NATCO PHARMA LTD.
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- ₹805
- Today's High:
- ₹833
- Open Price:
- ₹810.25
- 52W Low:
- ₹500.8276
- 52W High:
- ₹783
- Prev. Close:
- ₹812.35
- Volume:
- 49164
Company Statistics
- Market Cap.:
- ₹135.19 billion
- Book Value:
- 267.016
- Revenue TTM:
- ₹27.07 billion
- Operating Margin TTM:
- 29.58%
- Gross Profit TTM:
- ₹21.84 billion
- Profit Margin:
- 26.42%
- Return on Assets TTM:
- 9.3%
- Return on Equity TTM:
- 15.66%
Company Profile
NATCO PHARMA LTD. had its IPO on under the ticker symbol NATCOPHARM.
The company operates in the Healthcare sector and Drug Manufacturers-Specialty & Generic industry. NATCO PHARMA LTD. has a staff strength of 0 employees.
Stock update
Shares of NATCO PHARMA LTD. opened at ₹810.25 at the start of the last trading session i.e. 2023-09-13.
The stocks traded within a range of ₹805 - ₹833, and closed at ₹822.05.
This is a +1.19% increase from the previous day's closing price.
A total volume of 49,164 shares were traded at the close of the day’s session.
In the last one week, shares of NATCO PHARMA LTD. have slipped by -8.89%.
NATCO PHARMA LTD.'s Key Ratios
NATCO PHARMA LTD. has a market cap of ₹135.19 billion, indicating a price to book ratio of 2.2721 and a price to sales ratio of 4.2646.
In the last 12-months NATCO PHARMA LTD.’s revenue was ₹27.07 billion with a gross profit of ₹21.84 billion and an EBITDA of ₹9.65 billion. The EBITDA ratio measures NATCO PHARMA LTD.'s overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, NATCO PHARMA LTD.’s operating margin was 29.58% while its return on assets stood at 9.3% with a return of equity of 15.66%.
In Q1, NATCO PHARMA LTD.’s quarterly earnings growth was a negative -22.5% while revenue growth was a positive 50.1%.
NATCO PHARMA LTD.’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 19.26
- PEG
Its diluted EPS in the last 12-months stands at ₹39.19 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into NATCO PHARMA LTD.’s profitability.
NATCO PHARMA LTD. stock is trading at a EV to sales ratio of 3.8896 and a EV to EBITDA ratio of 14.1709. Its price to sales ratio in the trailing 12-months stood at 4.2646.
NATCO PHARMA LTD. stock pays annual dividends of ₹5.5 per share, indicating a yield of 1% and a payout ratio of 22.84%.
Balance sheet and cash flow metrics
- Total Assets
- ₹56.57 billion
- Total Liabilities
- ₹6.83 billion
- Operating Cash Flow
- ₹0
- Capital Expenditure
- ₹0
- Dividend Payout Ratio
- 22.84%
NATCO PHARMA LTD. ended 2024 with ₹56.57 billion in total assets and ₹0 in total liabilities. Its intangible assets were valued at ₹56.57 billion while shareholder equity stood at ₹48.74 billion.
NATCO PHARMA LTD. ended 2024 with ₹0 in deferred long-term liabilities, ₹6.83 billion in other current liabilities, in common stock, ₹0 in retained earnings and ₹552.00 million in goodwill. Its cash balance stood at ₹1.32 billion and cash and short-term investments were ₹0. The company’s total short-term debt was ₹0 while long-term debt stood at ₹0.
NATCO PHARMA LTD.’s total current assets stands at ₹30.00 billion while long-term investments were ₹0 and short-term investments were ₹10.30 billion. Its net receivables were ₹8.56 billion compared to accounts payable of ₹2.64 billion and inventory worth ₹7.43 billion.
In 2024, NATCO PHARMA LTD.'s operating cash flow was ₹0 while its capital expenditure stood at ₹0.
Comparatively, NATCO PHARMA LTD. paid ₹0.23 in dividends in 2024.
Other key metrics
- Current Trading Price
- ₹822.05
- 52-Week High
- ₹783
- 52-Week Low
- ₹500.8276
- Analyst Target Price
- ₹
NATCO PHARMA LTD. stock is currently trading at ₹822.05 per share. It touched a 52-week high of ₹783 and a 52-week low of ₹783. Analysts tracking the stock have a 12-month average target price of ₹.
Its 50-day moving average was ₹809.77 and 200-day moving average was ₹630.77 The short ratio stood at 0 indicating a short percent outstanding of 0%.
Around 5124.2% of the company’s stock are held by insiders while 1941.1% are held by institutions.
Frequently Asked Questions About NATCO PHARMA LTD.
Similar Industry Stocks (Drug Manufacturers-Specialty & Generic)
Most Active
Top Gainers
Top Losers
About
NATCO Pharma Limited, a pharmaceutical company, develops, manufactures, and markets finished dosage formulations and active pharmaceutical ingredients (APIs). It offers formulations in various therapeutic areas, including cancers of blood, liver, kidney, lung, brain, breast, ovary, etc.; and APIs in various categories, such as oncology, central nervous system, pain management, and CV care. The company also offers orthopedic products comprising bisphosphonates, which are oral and injectable drugs; and gastroenterology products consisting of novel drugs for chronic hepatitis-B and hepatitis-C, as well as contract manufacturing services. In addition, it provides cardiology and diabetology products for the treatment of hypertension, stable angina, and CHF; and agro chemicals and biological pest management solutions for management of insects, diseases, and weeds across a range of crops. The company markets its products in approximately 50 countries. NATCO Pharma Limited was incorporated in 1981 and is headquartered in Hyderabad, India.